Indefinite Delivery Contract 36E79726D0017

The Department of Veterans Affairs National Acquisition Center issued a single-award Indefinite Delivery Contract to Exelan Pharmaceuticals Inc. for the supply of Bumetanide Tablets, effective May 30, 2026, through May 29, 2027, with four one-year option periods and a ceiling value of $5,595,064.40. This unrestricted, non-set-aside procurement was conducted as a commercial item acquisition under Federal Acquisition Regulation Part 12 and represents a firm-fixed-price, requirements-type vehicle serving the VA, Department of Defense, Bureau of Prisons, Indian Health Service, and Federal Health Care Centers through their respective pharmaceutical prime vendor programs. Exelan Pharmaceuticals, headquartered in Boca Raton, Florida, will perform substantially all work at its primary facility and designated delivery locations, with performance requirements including provision of an exact drug name matching the product label, maintenance of a unique National Drug Code number assigned to the vendor's organization, and commitment to providing an uninterrupted source of supply throughout the contract period.

The original solicitation (RFP 36E79725R0068) identified estimated annual requirements spanning five different Bumetanide tablet strengths—0.5 milligrams, 1 milligram, and 2 milligrams—in both 100-tablet and 500-tablet package sizes, with annual usage estimates ranging from approximately 11,493 to 31,067 bottles depending on the specific strength and package configuration. Bumetanide is a loop diuretic medication utilized within federal healthcare systems for the treatment of edema and hypertension. Exelan's extensive portfolio of pharmaceutical supply contracts for the federal government, including single-award Indefinite Delivery Contracts with ceiling values exceeding $88 million for other medications, demonstrates the company's established capability and experience as a critical strategic supplier for federal pharmaceutical procurement requirements.